{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T23:46:22Z","timestamp":1772495182247,"version":"3.50.1"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>This article describes the Personalized Reimbursement Model (PRM) program methodology, limitations, achievement and perspectives in using real-world data of cancer drugs use to improve and personalize drug pricing and reimbursement in France.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>PRM platform aggregates Electronic Pharmacy Records (EPR) data from French medical centers (PRM centers) to build retrospective cohorts of patients treated with injectable cancer drugs in a hospital setting. Data extracted on January 1<jats:sup>st<\/jats:sup>, 2020, from breast cancer (BC) patients who received trastuzumab, trastuzumab emtansin or pertuzumab since January 1st, 2011, and from lung cancer (LC) patients who received bevacizumab or atezolizumab since January 1<jats:sup>st<\/jats:sup>, 2015, enabled recovering their injectable cancer drugs history from diagnosis date until December 30<jats:sup>th<\/jats:sup>, 2019, and served as dataset for assessment.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>123 PRM centers provided data from 30,730 patients (25,660 BC and 5,070 LC patients respectively). Overall, 20,942 (82%) of BC and 4,716 (93%) of LC patients were analyzed. Completion rate was above 98% for patients characteristics, diagnostic and treatment related data. PRM centers cover 48% and 33% of BC and LC patients in-hospital therapeutic management in France, respectively. Distribution of BC and LC patients therapeutic management, by medical center category and geographic location, was similar in PRM centers to all French medical centers, ensuring the representativeness of the PRM platform.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>PRM Platform enabled building a national database generating on demand Real-World Evidence based on EPR. This enabled the first performance-based risk-sharing arrangements based on PRM data, between the CEPS and Roche, for atezolizumab cancer immunotherapy in metastatic non-small cell lung cancer indication.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0267242","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T17:34:17Z","timestamp":1650389657000},"page":"e0267242","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5998-8285","authenticated-orcid":true,"given":"Pierre-Alexandre","family":"Squara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinh-Phuc","family":"Luu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Coudert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Machuron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Bachot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Samelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Florentin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Pinguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9chir","family":"Ben Hadj Yahia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"pone.0267242.ref001","unstructured":"Incidence and mortality historical data. 2020 [Cited 22 February 2021]. In: European Cancer Information System [Internet]. [graphics]. Available from: https:\/\/ecis.jrc.ec.europa.eu\/."},{"key":"pone.0267242.ref002","unstructured":"National estimates of cancer incidence and mortality in metropolitan France between 1990 and 2018. 2019 Jul [Cited 22 February 2021]. In: Public Health France [Internet]. [20 pages]. Available from: https:\/\/www.e-cancer.fr\/Expertises-et-publications\/Catalogue-des-publications\/National-estimates-of-cancer-incidence-and-mortality-in-metropolitan-France-between-1990-and-2018-Overview."},{"key":"pone.0267242.ref003","unstructured":"Pharmaceutical Innovation and Access to Medicines. 2018 [cited 22 February 2021]. In: OECD Health Policy Studies [internet]. [192 pages]. Available from: https:\/\/www.oecd.org\/health\/pharmaceutical-innovation-and-access-to-medicines-9789264307391-en.htm."},{"key":"pone.0267242.ref004","doi-asserted-by":"crossref","unstructured":"Challenges in access to oncology medicines: Policies and practices across the OECD and the EU. 2020 Nov 6 [cited 22 February 2021]. In: OECD Health Policy Studies [internet]. [109 pages]. Available from: https:\/\/dx.doi.org\/10.1787\/4b2e9cb9-en.","DOI":"10.1787\/4b2e9cb9-en"},{"key":"pone.0267242.ref005","unstructured":"In-hospital spending related to cancer drugs from the supplementary list (Liste en Sus). 2019 [cited 22 February 2021]. In: National Cancer Institute of France [internet]. [graphics]. Available from: https:\/\/lesdonnees.e-cancer.fr\/Themes\/Soins\/La-chimiotherapie\/Depenses-liees-aux-anticancereux-de-la-liste-en-sus-en-milieu-hospitalier#ind31206."},{"key":"pone.0267242.ref006","unstructured":"EFPIA Patients W.A.I.T Indicator 2019 Survey. 2019 [cited 22 February 2021]. In: European Federation of Pharmaceutical Industries and Associations [internet]. [57 pages]. Available from: https:\/\/www.efpia.eu\/media\/554526\/patients-wait-indicator-2019.pdf."},{"issue":"4","key":"pone.0267242.ref007","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s11523-015-0411-8","article-title":"French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends.","volume":"11","author":"C Chouaid","year":"2016","journal-title":"Target Oncol."},{"key":"pone.0267242.ref008","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.594549","article-title":"Companies\u2019 Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study.","volume":"11","author":"T Wang","year":"2020","journal-title":"Front Pharmacol."},{"key":"pone.0267242.ref009","unstructured":"Access to Personalised Oncology in Europe. 2020 Nov [cited 22 February 2021]. In: The London School of Economics and Political Science [internet]. [59 pages]. Available from: https:\/\/www.efpia.eu\/media\/580518\/access-to-personalised-oncology-in-europe.pdf"},{"issue":"9453","key":"pone.0267242.ref010","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cTo whom do the results of this trial apply?\u201d","volume":"365","author":"PM Rothwell","year":"2005","journal-title":"The Lancet"},{"key":"pone.0267242.ref011","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejca.2016.12.017","article-title":"The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials","volume":"74","author":"M Donia","year":"2017","journal-title":"Eur J Cancer"},{"issue":"4","key":"pone.0267242.ref012","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"P Sharma","year":"2017","journal-title":"Cell"},{"key":"pone.0267242.ref013","first-page":"69","article-title":"The use of real-world data in cancer drug development","volume":"101","author":"E Skovlund","year":"2018","journal-title":"Eur J Cancer Oxf Engl 1990."},{"issue":"Suppl 2","key":"pone.0267242.ref014","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00019053-200119002-00007","article-title":"Using health outcomes data to inform decision-making: healthcare payer perspective.","volume":"19","author":"PJ Lancry","year":"2001","journal-title":"PharmacoEconomics."},{"issue":"1","key":"pone.0267242.ref015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cpt.1426","article-title":"Real\u2010World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe","volume":"106","author":"A Cave","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"pone.0267242.ref016","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jval.2016.12.003","article-title":"Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.","volume":"20","author":"A Makady","year":"2017","journal-title":"Value Health."},{"issue":"1","key":"pone.0267242.ref017","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1186\/s12885-018-4958-5","article-title":"Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study","volume":"18","author":"A Scherpereel","year":"2018","journal-title":"BMC Cancer"},{"key":"pone.0267242.ref018","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejca.2020.10.012","article-title":"Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2\u2013targeted treatments: Results from the french personalized reimbursement model database (2011\u20132018).","volume":"141","author":"P Cottu","year":"2020","journal-title":"Eur J Cancer"},{"issue":"5","key":"pone.0267242.ref019","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jval.2013.04.011","article-title":"Performance-Based Risk-Sharing Arrangements\u2014Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force.","volume":"16","author":"LP Garrison","year":"2013","journal-title":"Value Health."},{"issue":"6","key":"pone.0267242.ref020","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.revmed.2014.11.009","article-title":"French health insurance databases: What interest for medical research?","volume":"36","author":"G Moulis","year":"2015","journal-title":"Rev M\u00e9decine Interne"},{"issue":"7","key":"pone.0267242.ref021","doi-asserted-by":"crossref","first-page":"A567","DOI":"10.1016\/j.jval.2015.09.1863","article-title":"Review of Policies And Perspectives on Real-World Data for Drug Development and Assessment (Imi-Getreal Deliverable).","volume":"18","author":"A Makady","year":"2015","journal-title":"Value Health."},{"issue":"5","key":"pone.0267242.ref022","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","article-title":"Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report.","volume":"10","author":"LP Garrison","year":"2007","journal-title":"Value Health."},{"issue":"01","key":"pone.0267242.ref023","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0039-1677917","article-title":"The French Health Data Hub and the German Medical Informatics Initiatives: Two National Projects to Promote Data Sharing in Healthcare.","volume":"28","author":"M Cuggia","year":"2019","journal-title":"Yearb Med Inform."},{"issue":"23","key":"pone.0267242.ref024","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-World Evidence\u2014What Is It and What Can It Tell Us?","volume":"375","author":"RE Sherman","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0267242.ref025","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1524-4733.2009.00601.x","article-title":"Good Research Practices for Comparative Effectiveness Research: Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report\u2014Part II.","volume":"12","author":"E Cox","year":"2009","journal-title":"Value Health."},{"key":"pone.0267242.ref026","first-page":"i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","author":"JA Sterne","year":"2016","journal-title":"BMJ. October"},{"issue":"2","key":"pone.0267242.ref027","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jval.2011.12.010","article-title":"Prospective Observational Studies to Assess Comparative Effectiveness: The ISPOR Good Research Practices Task Force Report.","volume":"15","author":"ML Berger","year":"2012","journal-title":"Value Health."},{"issue":"8","key":"pone.0267242.ref028","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jval.2017.08.3019","article-title":"Good Practices for Real\u2010World Data Studies of Treatment and\/or Comparative Effectiveness: Recommendations from the Joint ISPOR\u2010ISPE Special Task Force on Real\u2010World Evidence in Health Care Decision Making.","volume":"20","author":"ML Berger","year":"2017","journal-title":"Value Health."},{"issue":"1","key":"pone.0267242.ref029","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0337","article-title":"The Oncology Data Network (ODN): A Collaborative European Data\u2010Sharing Platform to Inform Cancer Care.","volume":"25","author":"D Kerr","year":"2020","journal-title":"The Oncologist."},{"issue":"10","key":"pone.0267242.ref030","doi-asserted-by":"crossref","first-page":"e1428","DOI":"10.1634\/theoncologist.2019-0855","article-title":"The Oncology Data Network (ODN): Methodology, Challenges, and Achievements.","volume":"25","author":"A Woolmore","year":"2020","journal-title":"The Oncologist."},{"key":"pone.0267242.ref031","unstructured":"European Health Data Space. 2020 [cited 22 February 2021]. In: European Commission [internet]. [about 1 screen] Available from: https:\/\/ec.europa.eu\/health\/ehealth\/dataspace_en."},{"issue":"9","key":"pone.0267242.ref032","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jval.2020.04.002","article-title":"Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing\u2014Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.","volume":"23","author":"LS Orsini","year":"2020","journal-title":"Value Health."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0267242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T17:34:46Z","timestamp":1650389686000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0267242"}},"subtitle":[],"editor":[{"given":"Wen-Wei","family":"Sung","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0267242","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]}}}